Welcome to our dedicated page for NEUROONE MEDICAL TECHNOLOGIES SEC filings (Ticker: NMTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NEUROONE MEDICAL TECHNOLOGIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NEUROONE MEDICAL TECHNOLOGIES's regulatory disclosures and financial reporting.
Insider sale reported: Mark Christianson, Business Development Director of NeuroOne Medical Technologies (NMTC), reported a disposition of 253 shares of the company's common stock on 09/30/2025 at a reported price of $0.8886 per share. After the transaction he beneficially owns 230,985 shares in a direct capacity. The Form 4 was signed by Emily Johns by power of attorney on 10/01/2025. The filing indicates the report was made by one reporting person and lists Christianson\'s Eden Prairie, MN address.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) director and CEO David A. Rosa reported a small sale of 2,458 shares of common stock at $0.8886 per share on 09/30/2025, leaving beneficial ownership of 1,156,373 shares. The filing documents a routine insider disposition while the reporting person retains a substantial equity stake, and the transaction was disclosed under Section 16 rules.
NeuroOne Medical Technologies (NMTC) insider sale disclosed on Form 4. The reporting person, Mark Christianson, identified as a director and Business Development Director, sold 30,000 shares of common stock on 09/05/2025 at a weighted average price of $0.7401 per share, with individual sale prices ranging from $0.7400 to $0.7518. After the reported transactions, the filing shows 231,238 shares beneficially owned. The Form 4 was signed by a power of attorney on 09/09/2025. No derivative securities are reported on this form.
NeuroOne Medical Technologies (NMTC) filed a Form 144 disclosing a proposed sale of 30,000 common shares through Edward Jones with an aggregate market value of $24,210. The filing lists 49,817,835 shares outstanding and an approximate sale date of 08/20/2025. The shares were acquired on 07/01/2025 as an award from NeuroOne Medical Technologies; the record shows 622,000 shares were acquired on that date and payment/nature is indicated as awarded. The filer reports no securities sold in the past three months and affirms they are not aware of undisclosed material adverse information about the issuer.
NeuroOne Medical Technologies Corporation reported that on August 18, 2025 it received U.S. Food and Drug Administration 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System. This clearance allows the company to market the device for procedures that create radiofrequency lesions to treat pain, and for lesioning nerve tissue in functional neurosurgical procedures. The authorization gives NeuroOne regulatory approval to commercialize this system in the United States for these specific neurosurgical applications.
NeuroOne Medical Technologies Corporation filed an update about its existing at-the-market stock sales program. On August 15, 2025, the company filed a new Prospectus Supplement covering the potential offer and sale of up to $6.75 million of common shares through JonesTrading Institutional Services LLC as sales agent under a previously signed Capital on Demand Sales Agreement.
The shares will be issued under an effective registration statement, and any sales will be made only by means of the updated Prospectus. Honigman LLP provided a legal opinion on the validity of the shares, which is included as an exhibit to this report.
NeuroOne Medical Technologies Corporation is updating its at-the-market equity program to register up to $6,750,000 of common stock for potential future sales through JonesTrading Institutional Services LLC as sales agent. This supplements earlier prospectus supplements under the same Capital on Demand Sales Agreement. The company has already sold approximately $8,000,600 under the agreement using the prior prospectus. The filing notes a non-affiliate market value of about $49.75 million for its common stock, based on 48,301,009 shares held by non-affiliates at $1.03 per share as of July 22, 2025, while the last reported Nasdaq price was $0.83 per share on August 14, 2025.
Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach disclosed beneficial ownership of 4,000,000 common shares of NeuroOne Medical Technologies, representing 8.03% of the company’s common stock. The filing states Bleichroeder LP is an investment adviser and that these shares are held in the ordinary course of business for its clients.
The reporting persons report sole voting and sole dispositive power over the 4,000,000 shares and no shared voting or dispositive power. The filing also notes the stake was not acquired to change or influence control of the issuer and that client beneficiaries retain rights to dividends and sale proceeds.
NeuroOne Medical Technologies reported growing product sales and improved liquidity for the period ended June 30, 2025. Product revenue increased to $1.70 million in the quarter and $6.36 million year-to-date, while the Company also recognized $3.0 million of license revenue from an amended distribution agreement with Zimmer, which was recorded in the nine months ended June 30, 2025. Total assets were $10.82 million and cash and cash equivalents rose to $8.04 million, up from $1.46 million at September 30, 2024, largely reflecting an April 2025 equity financing that generated approximately $8.24 million of net proceeds.
Despite revenue gains, NeuroOne reported a net loss of $1.50 million for the quarter and $1.99 million for the nine months, with an accumulated deficit of $76.99 million. The Company reduced its warrant liability from $2.14 million to $1.04 million, and notes continued concentration risk with one customer accounting for the majority of product sales. Management states available cash plus anticipated Zimmer-related revenue and planned expense reductions should fund operations for at least twelve months, but additional financing may be required thereafter.
NeuroOne Medical Technologies Corporation filed a Form 8-K reporting a material event by submitting a Press Release dated August 14, 2025. The filing identifies the company’s common stock ticker as NMTC on The Nasdaq Stock Market and lists an exhibit reference Exhibit 99.1 for the press release and a cover page interactive data file. The document is signed by David Rosa, Chief Executive Officer. The filing text provided here is brief and does not include the press release content, financial results, or details about the reported material event.